Cargando…

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses

BACKGROUND: Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeller, Scott, Zun, Leslie, Cassella, James V., Spyker, Daniel A., Yeung, Paul P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal College of Psychiatrists 2017
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680528/ https://www.ncbi.nlm.nih.gov/pubmed/29163985 http://dx.doi.org/10.1192/bjpo.bp.117.005363

Ejemplares similares

Effect of Smoking on the Pharmacokinetics of Inhaled Loxapine
por: Takahashi, Lori H., et al.
Publicado: (2014)

A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers
por: Cassella, James V., et al.
Publicado: (2015)

Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens
por: Spyker, Daniel A., et al.
Publicado: (2015)

Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo‐controlled drug–drug interaction study
por: Spyker, Daniel A., et al.
Publicado: (2015)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden, Justin, et al.
Publicado: (2019)

Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
por: Citrome, Leslie
Publicado: (2013)

M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2020)

Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change
por: Pacciardi, Bruno, et al.
Publicado: (2019)

LOXAPINE IN THE TREATMENT OF SCHIZOPHRENIA : AN OPEN STUDY
por: Emmanuel, S.A., et al.
Publicado: (1997)

Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series
por: Roncero, Carlos, et al.
Publicado: (2017)

S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Ostergaard, Soren Dinesen, et al.
Publicado: (2018)

Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder
por: San, L., et al.
Publicado: (2017)

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
por: Lefort-Besnard, Jérémy, et al.
Publicado: (2018)

Inhaled Loxapine for the Treatment of Psychiatric Agitation in the Prehospital Setting: A Case Series
por: Cester-Martínez, Armando, et al.
Publicado: (2017)

Clinical Outcomes in Patients Taking Inhaled Loxapine, Haloperidol, or Ziprasidone in the Emergency Department
por: McDowell, Marc, et al.
Publicado: (2019)

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2019)

The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review
por: de Berardis, Domenico, et al.
Publicado: (2017)

Revisiting loxapine: a systematic review
por: Popovic, Dina, et al.
Publicado: (2015)

Loxapine in patient with clozapine-resistant psychosis
por: Erley, Jennifer, et al.
Publicado: (2021)

Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
por: Zeller, Scott L., et al.
Publicado: (2016)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
por: Huang, Jiang, et al.
Publicado: (2021)

The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender
por: Sulejmanpasic, Gorana, et al.
Publicado: (2023)

Effects of intravenous loxapine on systemic and brain hemodynamics
por: Lescot, T, et al.
Publicado: (2003)

Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time
por: Ferrer, Marc, et al.
Publicado: (2022)

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
por: Krekels, EHJ, et al.
Publicado: (2017)

M40. ECT VERSUS SHAM FOR CLOZAPINE RESISTANT SCHIZOPHRENIA: A SECONDARY ANALYSIS OF A PILOT STUDY BASED ON PANSS-30 FACTOR ANALYTIC DIMENSIONS AND THE PANSS-6
por: Luciana Melzer-Ribeiro, Debora, et al.
Publicado: (2020)

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
por: Sharafi, Mohammad
Publicado: (2005)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
por: Hieronymus, Fredrik, et al.
Publicado: (2021)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Is the PANSS used correctly? a systematic review
por: Obermeier, Michael, et al.
Publicado: (2011)

Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia
por: Jerrell, Jeanette M., et al.
Publicado: (2013)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials
por: Podichetty, Jagdeep T., et al.
Publicado: (2021)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

Changes in neurotransmitter levels, brain structural characteristics, and their correlation with PANSS scores in patients with first-episode schizophrenia
por: Xu, Xian-Jia, et al.
Publicado: (2023)

Loxapine to control agitation during weaning from mechanical ventilation
por: Gaudry, Stéphane, et al.
Publicado: (2017)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Considering Loxapine Instead of Clozapine: A Case Series and Literature Review
por: Shrestha, Shristi, et al.
Publicado: (2021)

Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
por: Montoya, Alonso, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kvcoih132206p4vrtjefceusvj